Following a spate of large-scale pharma investments in the U.S. last year, German conglomerate Bayer is advancing its own plans to expand in America, in a move the company is framing as the ...

Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic ...

In three deals each worth $2 billion or more, AstraZeneca is investing in Summit Therapeutics with a focus on ivonescimab and ...

Already sharing the load on two biosimilar assets, Teva Pharmaceutical and Samsung Bioepis have elected to take their ...

While Foundayo’s insulin-matching potential in type 2 diabetes had been established in a topline readout earlier this year, ...

In Milan this week, Novo and Eli Lilly took the stage at the European Association for the Study of Diabetes 2026 meeting with ...

Taiho Pharmaceuticals, together with U.S.-based subsidiary Taiho Oncology, has inched closer to approval of another oral ...

BioNTech is set to shutter multiple sites in Germany, impacting about 1,800 jobs, after efforts to find buyers fell through.

Genentech is turning up the volume on breast cancer conversations in its “About Damn Time” campaign with Breastcancer.org and ...

Eli Lilly’s portfolio of weight loss and diabetes medications have become a dominant force in the market—but access to the ...

INS is Gazyva’s second immune-mediated indication, following an approval last October in adult lupus nephritis, a potentially ...

Although a clinical setback last year continues to loom in the background, AbbVie’s $8.7 billion bet on Cerevel Therapeutics ...